IL256618A - Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs - Google Patents

Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs

Info

Publication number
IL256618A
IL256618A IL256618A IL25661817A IL256618A IL 256618 A IL256618 A IL 256618A IL 256618 A IL256618 A IL 256618A IL 25661817 A IL25661817 A IL 25661817A IL 256618 A IL256618 A IL 256618A
Authority
IL
Israel
Prior art keywords
antibody
cell
complement activation
based drugs
activation product
Prior art date
Application number
IL256618A
Other languages
English (en)
Hebrew (he)
Original Assignee
Allegheny Singer Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allegheny Singer Res Institute filed Critical Allegheny Singer Res Institute
Publication of IL256618A publication Critical patent/IL256618A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5052Cells of the immune system involving B-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16ZINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00Subject matter not provided for in other main groups of this subclass
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
IL256618A 2015-07-31 2017-12-27 Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs IL256618A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199713P 2015-07-31 2015-07-31
PCT/US2016/044779 WO2017023781A1 (en) 2015-07-31 2016-07-29 Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs

Publications (1)

Publication Number Publication Date
IL256618A true IL256618A (en) 2018-03-29

Family

ID=57885963

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256618A IL256618A (en) 2015-07-31 2017-12-27 Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs

Country Status (7)

Country Link
US (1) US10067128B2 (enExample)
EP (1) EP3329278A4 (enExample)
JP (1) JP6674543B2 (enExample)
AU (1) AU2016303499B2 (enExample)
CA (1) CA2990722C (enExample)
IL (1) IL256618A (enExample)
WO (1) WO2017023781A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102604687B1 (ko) * 2017-02-01 2023-11-20 삼성전자주식회사 이미지 센서 및 그 제조 방법
AU2018333062B2 (en) 2017-09-15 2022-03-17 Beckman Coulter, Inc. Flow based assays for therapeutics

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4570872B2 (ja) 2001-09-10 2010-10-27 ユニヴァーシティ オブ ピッツバーグ 全身性紅斑性狼瘡および強皮症の診断およびモニタリング方法
US7588905B2 (en) 2003-04-16 2009-09-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification and monitoring of systemic lupus erythematosus
US8080382B2 (en) 2003-06-13 2011-12-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monitoring immunologic, hematologic and inflammatory diseases
EP2214014A1 (en) * 2004-05-11 2010-08-04 The University of Pittsburgh Monitoring immunologic, hematologic and inflammatory diseases
WO2006133450A2 (en) * 2005-06-08 2006-12-14 Duke University Anti-cd19 antibody therapy for the transplantation
AU2009305575A1 (en) 2008-10-16 2010-04-22 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (SLE) and other autoimmune diseases
WO2010054195A2 (en) 2008-11-07 2010-05-14 Centocor Ortho Biotech Inc. Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
WO2011047337A2 (en) 2009-10-16 2011-04-21 Exagen Diagnostics, Inc. Cell-based complement activation product algorithm for diagnosing systemic lupus erythematosus
EP2673644B1 (en) 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
US9075069B2 (en) 2011-12-13 2015-07-07 Baxter International Inc. Measurement of autoantibodies at low conductivity with increased sensitivity
WO2014020357A1 (en) 2012-08-02 2014-02-06 Sense Proteomic Limited Auto-antigen biomarkers for lupus
WO2014093268A1 (en) 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
CN111965358A (zh) * 2013-02-08 2020-11-20 阿勒格尼-辛格研究所 细胞结合的补体激活产物作为狼疮前期诊断性生物标志物
EP3092252B1 (en) * 2014-01-08 2019-09-18 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibody targeting cell surface deposited complement protein c3d and use thereof
RU2017107273A (ru) 2014-08-08 2018-09-10 Аллегени-Сингер Рисерч Инститьют Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров

Also Published As

Publication number Publication date
WO2017023781A1 (en) 2017-02-09
AU2016303499A1 (en) 2018-02-01
US10067128B2 (en) 2018-09-04
EP3329278A4 (en) 2019-01-16
JP6674543B2 (ja) 2020-04-01
CA2990722C (en) 2022-07-05
US20170030905A1 (en) 2017-02-02
AU2016303499B2 (en) 2020-07-02
EP3329278A1 (en) 2018-06-06
JP2018528439A (ja) 2018-09-27
CA2990722A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
ZA201801792B (en) Diatomite products
GB201610184D0 (en) Product
IL277601A (en) Process for the manufacture of a preparation containing gelatinmer acetate
EP3127624A4 (en) Die for bending-press forming
SG11201708341WA (en) Producing polyolefin products
GB201502721D0 (en) Product
GB2545092B (en) Separation process for laminar materials, such as graphene
GB201522232D0 (en) Combination product
SG10201913125PA (en) Fire-stopping product
BR112017008870A2 (pt) produto de petisco coextrusado
PL3169712T3 (pl) Związki diaryloetenowe podstawione grupą aminosilylową do polimeryzacji anionowej
EP3107398A4 (en) Triple-extruded snack product
GB201618090D0 (en) Product
PL3160985T3 (pl) Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylo-l-fenyloalaninoamidu
PL3020696T3 (pl) Sposób wytwarzania jednego lub większej ilości produktów reakcji
GB2542916B (en) Anti-back-out fastener for applications under vibration
PL3247489T3 (pl) Sposób wytwarzania porowatego produktu w proszku
ZA201703085B (en) Process for pressing delay elements for non-electric initiators
GB201608398D0 (en) Identifiable Chemical Product
GB201615464D0 (en) Product
EP3221741A4 (en) Lenticular product
HUE046584T2 (hu) Eljárás egy termék folyamatos elõállítására legalább kettõ, egymással összekapcsolt kémiai reakcióval
GB201622001D0 (en) Product
GB201614651D0 (en) Product
ZA201508241B (en) A passenger counter

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed